We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Take a look at our previous reports:

Annual Report

2017

View Report

Q1 Report

2018

View Report

H1 Report

2018

View Report

Q3 Report

2018

View Report
English | Dutch
Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2018

  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos group
    • Letter from the management
    • At a glance
    • Strategy
    • Think big
      • Our people
      • Committed to CSR
      • We deliver
    • Going concern statement
    • Risk management and internal control
    • The Galapagos share
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery platform
    • Filgotinib
      • Our filgotinib program in RA
      • Inflammatory bowel disease
        • Our filgotinib program in IBD
        • Clinical program with filgotinib in CD
        • Clinical program with filgotinib in UC
      • Other clinical programs with filgotinib
    • Fibrosis
    • Osteoarthritis
    • Atopic dermatitis
    • Toledo
    • Cystic fibrosis
  • Risk factors
    • Product development, regulatory approval and commercialization
    • Financial position and need for additional capital
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • CSR report
    • Our commitment
    • Improving people’s lives
    • Diversity and Human Capital Management
    • Business ethics
    • Environment, Health, and Safety
  • Corporate governance
    • Policies
    • Board of directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination of remuneration
      • Remuneration policy
      • Non-executive directors
      • Executive directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other executive committee members
      • Shares, warrants or other rights
      • Provisions for severance
      • Severance payments in 2018
      • Claw-back right
    • Conflict of interests and related parties
    • Code of Business Conduct and Ethics
    • Statement by the board of directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Significant accounting policies
        • 3. Critical accounting estimates and judgments
        • 4. Segment information
        • 5. Total revenues and other income
        • 6. Operating costs
        • 7. Staff costs
        • 8. Financial income/expenses
        • 9. Taxes
        • 10. Income/loss per share
      • Notes 11-20
        • 11. Intangible assets
        • 12. Property, plant and equipment
        • 13. Other non-current assets
        • 14. Research and development incentives receivables
        • 15. Trade and other receivables and other current assets
        • 16. Cash and cash equivalents
        • 17. Share capital
        • 18. Other reserves
        • 19. Translation differences
        • 20. Deferred tax
      • Notes 21-30
        • 21. Trade and other liabilities
        • 22. Deferred income
        • 23. Note to the cash flow statement
        • 24. Operating lease obligations
        • 25. Off-balance sheet arrangements
        • 26. Contingent assets and liabilities
        • 27. Retirement benefit plans
        • 28. Warrant plans
        • 29. Related parties
        • 30. Consolidated companies
      • Notes 31-33
        • 31. Financial risk management
        • 32. Statutory auditor’s remuneration
        • 33. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor

Financial statements

  • Consolidated financial statements
  • Notes to the consolidated financial statements
    • Notes 1-10
      • 1. General information
      • 2. Significant accounting policies
      • 3. Critical accounting estimates and judgments
      • 4. Segment information
      • 5. Total revenues and other income
      • 6. Operating costs
      • 7. Staff costs
      • 8. Financial income/expenses
      • 9. Taxes
      • 10. Income/loss per share
    • Notes 11-20
    • Notes 21-30
    • Notes 31-33
  • Non-consolidated financial statements

You are here:

  • Home
  • Financial statementsNotes to the consolidated financial statements
  • Notes 1-10
  • Notes 1-10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

Notes 1-10

Financial statements CSR report
Galapagos NV • Annual Report 2018
  • 1. General information
  • 2. Significant accounting policies
  • 3. Critical accounting estimates and judgments
  • 4. Segment information
  • 5. Total revenues and other income
  • 6. Operating costs
  • 7. Staff costs
  • 8. Financial income/expenses
  • 9. Taxes
  • 10. Income/loss (–) per share
previous pagenext page
Download Center
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 29 March 2019

Galapagos Annual Report 2018 (PDF)

Download the entire report as PDF.

Download PDF (2.7 MB)
English | Dutch
  • Downloads
  • Glossary of terms
  • © Copyright 2019 Galapagos NV
  • Colophon
  • Contact
  • Privacy notice
© Copyright 2019 Galapagos NV
nexxar - digital reporting evolved - Online Report